Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas
-
Published:2024-06
Issue:6
Volume:36
Page:353-361
-
ISSN:0936-6555
-
Container-title:Clinical Oncology
-
language:en
-
Short-container-title:Clinical Oncology
Author:
Ghosh Laskar S.ORCID,
Sinha S.,
Kumar A.,
Samanta A.,
Mohanty S.,
Kale S.,
Khan F.,
Lewis Salins S.,
Murthy V.
Funder
Tata Memorial Centre
Reference45 articles.
1. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients;Pignon;Radiother Oncol,2009
2. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma;Peng;Radiother Oncol,2012
3. DARS Trialist Group. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial;Nutting;Lancet Oncol,2023
4. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma;Gupta;PLoS One,2018
5. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial;Nutting;Lancet Oncol,2011